Chinese
Home
About Livzon
Milestones
Leaders' Caring
Company Honors
Cultural Vision
Contact Us
Media
Livzon News
Employment system
Investor Relations
Company Governance
Announcement
Financial Reports
ESG Report
Shareholder Returns
Stock Information
Sustainable Development
Human Development
Board Diversity Policy
Business Ethics
Supplier
Environment, Occupational Health and Safety (EHS)
Philanthropy
Privacy Policy
Tax policy
ESG Ratings and Honors
Product
Leading Products
Products List
ADR Reporting
R&D
R&D Platforms
Livzon microspheres
Livzon Bio
Livzon Research Institute
R&D Achievements
IP Achievements
Overseas Market
Overseas Business
Specialty Products
Certificates
Contact us
Join Us
Social Recruitment
Campus Recruitment
Compensation and Benefits
Appeal Against
Bidding procurement
Tender Announcement
Supplier Login
Supervision and Reporting
Contact information
Online message
ESG report
Shareholder returns
Stock information
Contacts
UNAUDITED INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026
File size:
2.8MB
File Type:
pdf
2026-08-21
CONNECTED TRANSACTIONS ACQUISITION OF SHARES IN XINBEIJIANG PHARMA
219.5KB
Letter to Non-registered Shareholders - Notification of publication of Interim Report 2026
371.2KB
Letter to Registered Shareholders - Notification of publication of Interim Report 2026
367.8KB
Interim Report 2026
3.5MB
Date of Board Meeting
153.9KB
2026-08-06
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2026
67.7KB
2026-08-03
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2026
2026-07-02
VOLUNTARY ANNOUNCEMENT OBTAINMENT OF THE DRUG REGISTRATION CERTIFICATE FOR RECOMBINANT HUMAN FOLLITROPIN ALFA SOLUTION FOR INJECTION
181.9KB
2026-06-01
VOLUNTARY ANNOUNCEMENT MARKETING AUTHORIZATION APPLICATION FOR LECANKITUG INJECTION ACCEPTED FOR REVIEW BY CHINA’S NATIONAL MEDICAL PRODUCTS ADMINISTRATION
